基于泛癌样本分析CDS1在乳腺癌中的表达及预后预测价值

doi:10.3969/j.issn.1004-616x.2025.05.005

摘要/Abstract

摘要： 目的：探讨CDP-二酰基甘油合成酶1(CDS1)在乳腺癌中的表达及预后价值。方法：利用癌症基因组图谱及基因表达综合数据库的RNA测序数据，分析CDS1在泛癌样本中的表达模式与预后预测价值，并探讨其与免疫亚型之间的关联。进一步对乳腺癌差异表达基因进行了功能富集分析，构建基因共表达网络。另通过免疫组织化学染色法(IHC)检测乳腺癌患者正常组织与癌组织中CDS1蛋白表达水平的差异。最后，构建并验证了一个包含CDS1表达的乳腺癌患者生存预后列线图模型。结果：与癌旁组织比较，CDS1在多种癌症组织中呈异常高表达(P<0.05)，在乳腺癌患者中CDS1高表达者较低表达者无复发生存期更短(P<0.01)，不同免疫分型的乳腺癌患者CDS1表达存在差异(P<0.01)。功能富集分析表明，CDS1可能参与脂质代谢调控通路及PI3K-Akt信号通路。相关性分析显示CDS1与PIK3CA和ERBB2基因显著相关(r=0.415，P<0.01和r=0.361，P<0.01)。IHC检测结果提示，乳腺癌组织中CDS1表达水平显著高于癌旁组织(P<0.01)，且其高表达的乳腺癌患者总生存期较低表达者更短(P<0.05)。此外，CDS1表达水平不同的乳腺癌患者HER-2表达水平存在显著差异(χ²=6.176，P=0.013)，构建的列线图模型表现出良好的生存预测能力(一致性指数为0.746，P=0.018)。结论：CDS1在乳腺癌中高表达，且与HER-2表达水平相关，其具有重要的预后预测价值，是一个潜在的乳腺癌生物标志物。

关键词: CDP-二酰基甘油合成酶1, 泛癌分析, 乳腺癌, 生物信息学, 预后

Abstract: OBJECTIVE：This study aimed to explore relationships between CDP-diacylglycerol synthase 1 (CDS1) and various cancers through bioinformatics analysis， and to further validate expression and prognostic value of CDS1 in breast cancer viain vitro experiments. METHODS：Using RNA sequencing (RNA-seq) data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO)，expression patterns and prognostic value of CDS1 in various cancer types were systematically analyzed. Relationships between CDS1 expression and immune subtypes were further investigated. Functional enrichment analysis of differentially expressed genes in breast cancer was performed，and a gene co-expression network was constructed. Immunohistochemistry (IHC) was used to detect differences in CDS1 protein expression levels between normal and cancerous tissues in breast cancer patients (BRCA). Lastly， a survival prediction nomogram model incorporating CDS1 expression was constructed and validated. RESULTS： Compared with adjacent non-tumorous tissues， CDS1 exhibited significantly higher expression in multiple cancer tissues (P <0.05). Importantly，breast cancer patients with high CDS1 expression demonstrated a significantly shorter recurrence-free survival (P <0.01). Furthermore， CDS1 expression differed significantly across breast cancer immune-histochemical subtypes (P <0.01). Functional enrichment analysis suggested that CDS1 was involved in the lipid metabolism regulatory pathway and the PI3K-Akt signaling pathway. Correlation analysis revealed significant associations between CDS1 expression and expression of PIK3CA (r=0.415， P <0.01) and ERBB2 (r=0.361， P <0.01). IHC results confirmed that CDS1 expression was significantly elevated in breast cancer tissues compared to adjacent tissues (P <0.01)， and correlated with shorter overall survival in patients with high expression (P <0.05). Additionally， HER-2 expression showed significant variations among breast cancer patients with different CDS1 expression levels (χ²= 6.176， p=0.013). The constructed nomogram exhibited good predictive performance for survival (concordance index=0.746， p=0.018). CONCLUSION： CDS1 was highly expressed in breast cancer and was significantly correlated with HER-2 expression， making it a valuable prognostic biomarker. Its potential role in lipid metabolism and the PI3K-Akt signaling pathway suggests that CDS1 contributed to breast cancer progression. The constructed nomogram model incorporating CDS1 expression provides an effective tool for survival prediction in breast cancer patients.

Key words: CDS1, pan-cancer analysis, breast cancer, bioinformatics, prognosis

中图分类号:

R737.9

李佳容, 林俊豪, 邱昭龙, 朱祉琴, 陈逢生. 基于泛癌样本分析CDS1在乳腺癌中的表达及预后预测价值[J]. 癌变·畸变·突变, 2025, 37(5): 375-382.

LI Jiarong, LIN Junhao, QIU Zhaolong, ZHU Zhiqin, CHEN Fengsheng. Expression and prognostic value of CDS1 in breast cancer based on pan-cancer analysis[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2025, 37(5): 375-382.

参考文献

[1] BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] ADAMS S C, NAMBIAR A K, BRESSLER E M, et al. Immunotherapies for locally aggressive cancers[J]. Adv Drug Deliv Rev, 2024, 210: 115331.
[3] YE F, DEWANJEE S, LI Y H, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer [J]. Mol Cancer, 2023, 22(1): 105.
[4] MAAN M, PETERS J M, DUTTA M, et al. Lipid metabolism and lipophagy in cancer[J]. Biochem Biophys Res Commun, 2018, 504(3): 582-589.
[5] MUKHERJEE A, BILECZ A J, LENGYEL E. The adipocyte microenvironment and cancer[J]. Cancer Metastasis Rev, 2022, 41(3): 575-587.
[6] D’SOUZA K, KIM Y J, BALLA T, et al. Distinct properties of the two isoforms of CDP-diacylglycerol synthase[J]. Biochemistry, 2014, 53(47): 7358-7367.
[7] INGLIS-BROADGATE S L, OCAKA L, BANERJEE R, et al. Isolation and characterization of murine Cds (CDP-diacylglycerol synthase) 1 and 2[J]. Gene, 2005, 356: 19-31.
[8] XU Y Q, MAK H Y, LUKMANTARA I, et al. CDP-DAG synthase 1 and 2 regulate lipid droplet growth through distinct mechanisms[J]. J Biol Chem, 2019, 294(45): 16740-16755.
[9] YEH K T, TANG K P, CHEN Y L, et al. Methylation inactivates expression of CDP-diacylglycerol synthase 1(CDS1) in hepatocellular carcinoma[J]. Cancer Genomics Proteomics, 2006, 3(3/4): 231-238.
[10] LI T W, FAN J Y, WANG B B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110.
[11] TANG Z F, KANG B X, LI C W, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): 556-560.
[12] WU C L, JIN X F, TSUENG G, et al. BioGPS: building your own mash-up of gene annotations and expression profiles[J]. Nucleic Acids Res, 2016, 44(D1): D313-D316.
[13] ZHOU G Y, SOUFAN O, EWALD J, et al. NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression profiling and meta-analysis[J]. Nucleic Acids Res, 2019, 47(W1): 234-241.
[14] MAGAKI S, HOJAT S A, WEI B W, et al. An introduction to the performance of immunohistochemistry[J]. Methods Mol Biol, 2019, 1897: 289-298.
[15] RU B B, WONG C N, TONG Y, et al. TISIDB: an integrated repository portal for tumor-immune system interactions[J]. Bioinformatics, 2019, 35(20): 4200-4202.
[16] EPAND R M. Features of the phosphatidylinositol cycle and its role in signal transduction[J]. J Membr Biol, 2017, 250(4): 353-366.
[17] BLUNSOM N J, COCKCROFT S. Phosphatidylinositol synthesis at the endoplasmic reticulum[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020, 1865(1): 158471.
[18] EPPENBERGER-CASTORI S, KLINGBIEL D, RUHSTALLER T, et al. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99[J]. BMC Cancer, 2020, 20(1): 114.
[19] ZHONG X Y, ZENG C T, HU S L, et al. CDP-diacylglycerol synthase 1 promotes proliferation, invasion, and metastasis in hepatocellular carcinoma[J]. J Biol Regul Homeost Agents, 2024, 38(1): 573-584.
[20] BROWNE I M, OKINES A F C. Resistance to targeted inhibitors of the PI3K/AKT/mTOR pathway in advanced oestrogenreceptor-positive breast cancer[J]. Cancers, 2024, 16(12): 2259.
[21] SCHLAM I, TARANTINO P, TOLANEY S M. Overcoming resistance to HER2-directed therapies in breast cancer[J]. Cancers, 2022, 14(16): 3996.
[22] SWAIN S M, MILES D, KIM S B, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study [J]. Lancet Oncol, 2020, 21(4): 519-530.
[23] CORTES J, RUGO H S, CESCON D W, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer [J]. N Engl J Med, 2022, 387(3): 217-226.
[24] SCHMID P, CORTES J, DENT R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer[J]. N Engl J Med, 2022, 386(6): 556-567.
[25] CARDOSO F, O??SHAUGHNESSY, LIU Z Z, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial[J]. Nat Med, 2025, 31(2): 442-448.
[26] SCHLAM I, CORTI C, SAMMONS S, et al. Checkpoint inhibition for early-stage hormone receptor-positive breast cancer[J]. Expert Opin Biol Ther, 2024, 24(6): 511-520.